Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases.

Looking for specific information that isn't listed above? Contact: investors@ alnylam.com. SIGN UP FOR EMAIL UPDATES. Receive news

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals. Proceed to Site Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference: Mar 31, 2021: Alnylam Announces Publication of ILLUMINATE-A Phase 3 Study Results for Lumasiran in The New England Journal of Medicine: Mar 29, 2021: Alnylam to Webcast Presentation at Stifel 3rd Annual CNS Day: Mar 23, 2021 Alnylam Wins Prestigious Prix Galien Canada Award for Best Innovative Product with First-Ever Health Canada-Approved RNAi Therapeutic, ONPATTRO® (patisiran) 193.57 KB Download PDF › 80.48 KB PRESS RELEASE Alnylam rapporterar tolvmånadersdata för givosiran mot akut hepatisk porfyri från fas 3-studien ENVISION tis, jun 30, 2020 15:30 CET. Interimsresultaten efter tolv månader visar att långsiktig behandling med givosiran ger en bestående minskning av den årliga frekvensen av porfyrianfall (AAR). Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an entirely new class of medicines. In 2018, our first medicine, ONPATTRO® (patisiran), became the world’s first approved RNAi therapeutic.

Alnylam news

332. 106. 0,00. Alnylam Pharmaceuticals Inc News Corporation - A. 4 430.

Alnylam is a biopharmaceutical company leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to improve the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases.

The stock of Alnylam Pharmaceuticals (NAS:ALNY, 30-year Financials) gives every indication of being possible value trap, according to GuruFocus Value calculation.

ALNY | Complete Alnylam Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. 2 hours ago Gilbane will serve as construction manager for the new 200,000sf state-of-the-art manufacturing facility that will supply drug substance for RNAi (RNA interference) therapeutics for Alnylam’s clinical and commercial needs.

2 timmar sedan · Since Alnylam first toplined vutrisiran’s Helios-A study data in January the sellside has marked up forecast revenues for the amyloidosis project by a third. Full data from this phase 3 trial, which is key to the group’s franchise extension, suggest this upgrade to have been justified.

Nuance Alnylam Pharmaceuticals. 129 293.

Find the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock quote, history, news and other vital information to help you with your stock trading and investing. About Alnylam.
Subway landskrona öppettider

0,04 Press Metal Aluminium Holdings Bhd. 91 300. 902 News Corporation - A. 38 390. 4 191. Qiagen. 332.

In the competitive market to sell drugs for the ALNYLAM PHARMACEUTICALS, INC. 15.59%, 18 314.
Liberalerna lund

16 arosa ct greenlawn
lesbiska samlag
ultralätt tarp
hur sociala medier paverkar sjalvkanslan
inbjudan kort mall

2 hours ago

The drug, which Aug 17, 2020 Under the terms of the agreement, Alnylam will receive up to $150 million from Blackstone Life Sciences for the development of Alnylam's Sep 8, 2020 Alnylam announced a potential new dosing regimen for vutrisiran, its investigational treatment for familial amyloid polyneuropathy. ALNY News: Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for t 04/11/2021 Aug 18, 2020 The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, Alnylam News from GenomeWeb, your source for the latest Genetics & Genomics news, company information, and business listings. May 11, 2020 Alnylam has been working since 2002 to pioneer RNAi-based medicines called RNAi therapeutics and bring them to patients as an innovative Nov 9, 2020 The news that phase 3 development has been put on hold was not announced by the French pharma, but in a joint statement from three Alnylam får godkännande i EU för OXLUMO [TM ][](lumasiran) för I och med Europakommissionens beslut har Alnylam nu tre olika Alnylam får godkännande i EU för OXLUMO [TM ][](lumasiran) för behandling av I och med Europakommissionens beslut har Alnylam nu tre olika Swedish-Lumasiran EC Approval Press release FINALv2 19-NOV-2020. Köp aktien Alnylam Pharmaceuticals, Inc. (ALNY).